Pre-clinical data is supportive of izicopan's renal disease potential but does not change near-term fundamentals. Watch for Phase 2/3 clinical data readouts in ANCA-associated vasculitis and any partnership announcements for izicopan.
Price Chart
Executive Summary
InflaRx presented pre-clinical data on izicopan at Kidney Week 2026, showing statistically significant renal protection in two hamster kidney injury models (IRI and UUO) compared to vehicle. The data is supportive but early-stage (pre-clinical), and the filing contains no financial figures, guidance changes, or clinical trial results that would move the stock near-term.
Key Facts
- Pre-clinical data on izicopan presented at ASN Kidney Week 2026 (Oct 21-25, Denver)
- In IRI model: single 100 mg/kg oral dose significantly reduced creatinine and BUN (p<0.001) and improved histopathological scores (p<0.05)
- In UUO model: daily oral dosing for 14 days significantly reduced BUN (p<0.001) and improved histopathological scores (p<0.05); numerical trend toward reduced fibrosis (p=NS)
- Structural modeling suggests izicopan has reduced CYP3A4/5 time-dependent inhibition vs avacopan
- Company is planning development in ANCA-associated vasculitis and additional renal indications
- No financial data, revenue, earnings, guidance, or clinical trial results reported in this filing
Financial Impact
No financial impact — pre-clinical data only, no revenue or expense figures disclosed
Risk Factors
- Pre-clinical results may not translate to human clinical efficacy
- No timeline provided for next clinical milestones
- Competition from avacopan (already marketed C5aR inhibitor) and other complement-targeting therapies
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001140361-26-040509 |
| Document: ef20084212_6k.htm | 0001140361-26-040509 |
| Document: 0001140361-26-040509-index-headers.html | 0001140361-26-040509 |
| Document: 0001140361-26-040509-index.html | 0001140361-26-040509 |
| Document: 0001140361-26-040509.txt | 0001140361-26-040509 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers